Clincosm LogoSign in Get a demo

A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects

Sponsor
Zeno Alpha Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT04561752
Collaborator
(none)
20
Enrollment
1
Location
2
Arms
1.4
Actual Duration (Months)
13.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a single-center, randomized, open-label, two-period, 2-way crossover food effect study to determine the comparative bioavailability of ZN-c5 under fed and fasting conditions, following single-dose administration of ZN-c5 capsules (150mg).

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
All participants will receive the same treatment but are randomized to one of two different treatment sequences in fed and fasted states.All participants will receive the same treatment but are randomized to one of two different treatment sequences in fed and fasted states.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Randomized, Open-Label, 2-Way Crossover, Single-Dose Food Effect Study of ZN-c5 in Healthy Adult Post-Menopausal Female Subjects
Actual Study Start Date :
Nov 2, 2020
Actual Primary Completion Date :
Dec 11, 2020
Actual Study Completion Date :
Dec 16, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment Sequence A-B

Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.

Drug: ZN-c5
ZN-c5 is the study drug.
Experimental: Treatment Sequence B-A

Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.

Drug: ZN-c5
ZN-c5 is the study drug.

Outcome Measures

Primary Outcome Measures

  1. AUC0-t [Days 1-4]

    Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time

  2. Cmax [Days 1-4]

    Maximum concentration

  3. Tmax [Days 1-4]

    Time to maximum concentration

  4. AUC0-infinity [Days 1-4]

    Area under the plasma concentration-time curve (AUC) from time zero to infinity

Secondary Outcome Measures

  1. Assess the incidence, frequency, and severity of treatment-emergent adverse events (TEAEs) [Approximately 45 days]

    Safety and tolerability of ZN-c5

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Healthy female volunteers

  • Body mass index (BMI) between > or = 18.0 kg/m2 and < or = 29.9 kg/m2, and a body weight > or = 50kg and < or = 100kg at Screening

  • Non-smoker and must not have used any tobacco products within 2 months prior to Screening, or if a smoker must be currently (and for the last 2 months prior to screening) smoking < or = 2 cigarettes or equivalent per week. Current smokers must be willing to abstain from the use of tobacco and products containing nicotine from 14 days prior to administration of study drug and through the EOS visit.

  • No relevant dietary restrictions, and be willing to consume a high calorie, high fat breakfast and other standard meals provided during the domiciled periods of the study

  • Post-menopausal for > or = 24 months. Status will be confirmed through testing of follicle-stimulating hormone (FSH) levels > or = 40 IU/L at Screening. Participants that are post-menopausal for < or = 24 months are still potentially eligible, but will be required to have a negative serum pregnancy test result at Screening and negative urine pregnancy test result prior to study drug administration.

Exclusion Criteria:

  • Any condition likely to affect the participant's ability to consume the standard meal provided during the domiciled periods of the study, or any condition that may make it difficult for the patient to comply with the requirement for fasting during the study

  • Blood donation or significant blood loss within 60 days prior to the first study drug administration

  • Plasma donation within 7 days prior to the first study drug administration

  • Fever (body temperature > or = 38C) or symptomatic viral or bacterial infection or febrile illness within 2 weeks prior to Screening

  • Positive serum pregnancy test at Screening or urine pregnancy test prior to administration of study drug (for participants who are post-menopausal for < or = 24 months only)

  • Positive toxicology screening panel or alcohol breath test

  • History of substance abuse or dependency or history of recreational intravenous (IV) drug use over the last 5 years (by self-declaration)

  • Regular alcohol consumption within the 6 months prior to study drug administration, defined as > 21 alcohol units per week

Contacts and Locations

Locations

Site City State Country Postal Code
1 Site 1 Christchurch New Zealand 8011

Sponsors and Collaborators

  • Zeno Alpha Inc.

Investigators

  • Study Chair: Dimitris Voliotis, Zeno Alpha Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zeno Alpha Inc.
ClinicalTrials.gov Identifier:
NCT04561752
Other Study ID Numbers:
  • ZN-c5-006
First Posted:
Sep 24, 2020
Last Update Posted:
Dec 23, 2020
Last Verified:
Dec 1, 2020
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Zeno Alpha Inc.
Randomized
Postmenopause
Female

Study Results

No Results Posted as of Dec 23, 2020